Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$891M |
| 2 |
Union Pacific
UNP
|
+$622M |
| 3 |
Salesforce
CRM
|
+$418M |
| 4 |
Edwards Lifesciences
EW
|
+$405M |
| 5 |
lululemon athletica
LULU
|
+$347M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caterpillar
CAT
|
+$680M |
| 2 |
Texas Instruments
TXN
|
+$585M |
| 3 |
RHT
Red Hat Inc
RHT
|
+$571M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$558M |
| 5 |
Parker-Hannifin
PH
|
+$556M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.09% |
| 2 | Healthcare | 17.49% |
| 3 | Consumer Discretionary | 17.05% |
| 4 | Financials | 12.69% |
| 5 | Communication Services | 11.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Nutrien
NTR
$33.9B
| $13.8M | 0.02% |
293,024
+24,953
| +9% | +$1.3M |
|
402
Cardlytics
CDLX
$22.1M
| $13.7M | 0.02% |
126,435
+46,585
| +58% | +$7.85M |
|
|
BRKL
403
DELISTED
Brookline Bancorp
BRKL
| $13.6M | 0.02% |
985,206
-917,737
| -48% | -$13.8M |
|
|
ABMD
404
DELISTED
Abiomed Inc
ABMD
| $13.5M | 0.02% |
41,543
+861
| +2% | +$299K |
|
|
CBIO
405
Crescent Biopharma
CBIO
$555M
| $13.5M | 0.02% |
14,221
-767
| -5% | -$923K |
|
406
Travere Therapeutics
TVTX
$5.33B
| $13.4M | 0.01% |
590,504
-203,815
| -26% | -$5.07M |
|
407
Arcosa
ACA
$7.13B
| $13.2M | 0.01% |
+477,878
| New | +$13.1M |
|
408
Dorman Products
DORM
$3.98B
| $13.1M | 0.01% |
145,376
+801
| +0.6% | +$64K |
|
|
MRNS
409
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $13.1M | 0.01% |
1,138,690
+663,059
| +139% | +$13.4M |
|
410
Equinor
EQNR
$96.8B
| $12.6M | 0.01% |
+593,845
| New | +$14.6M |
|
|
PXD
411
DELISTED
Pioneer Natural Resource Co.
PXD
| $12.6M | 0.01% |
95,572
-4,402
| -4% | -$673K |
|
412
MPLX
MPLX
$58.5B
| $12.4M | 0.01% |
409,097
-19,167
| -4% | -$640K |
|
413
Spotify
SPOT
$107B
| $12.2M | 0.01% |
107,894
-6,157
| -5% | -$861K |
|
414
Keurig Dr Pepper
KDP
$43B
| $12.1M | 0.01% |
471,865
+61,009
| +15% | +$1.55M |
|
|
KA
415
DELISTED
Kineta, Inc. Common Stock
KA
| $12.1M | 0.01% |
26,669
+311
| +1% | +$211K |
|
416
iRhythm Holdings
IRTC
$3.91B
| $11.8M | 0.01% |
170,045
+55,594
| +49% | +$4.21M |
|
417
Halliburton
HAL
$26.4B
| $11.8M | 0.01% |
442,473
-1,615,645
| -79% | -$54.5M |
|
|
AM
418
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $11.7M | 0.01% |
544,718
+91,638
| +20% | +$2.59M |
|
|
EPZM
419
DELISTED
Epizyme, Inc
EPZM
| $11.6M | 0.01% |
1,876,995
-324,042
| -15% | -$2.47M |
|
420
Heritage Financial
HFWA
$1.21B
| $11.5M | 0.01% |
388,572
+147,795
| +61% | +$4.83M |
|
|
OLBK
421
DELISTED
Old Line Bancshares, Inc.
OLBK
| $11.5M | 0.01% |
438,758
+4,485
| +1% | +$130K |
|
422
American Express
AXP
$228B
| $11.4M | 0.01% |
+119,535
| New | +$12.5M |
|
423
ManpowerGroup
MAN
$2.41B
| $11.4M | 0.01% |
175,539
-99,772
| -36% | -$7.58M |
|
|
ENLK
424
DELISTED
EnLink Midstream Partners, LP
ENLK
| $11.4M | 0.01% |
1,031,557
-48,333
| -4% | -$713K |
|
|
NUVA
425
DELISTED
NuVasive, Inc.
NUVA
| $11.3M | 0.01% |
227,230
+3,991
| +2% | +$240K |
|
Similar funds
Jennison Associates's Q4 2018 Portfolio in Review
As of Q4 2018, Jennison Associates held 753 positions worth $89.4B, down 18% from $109B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jennison Associates's Q4 2018 filing shows 95 new, 255 increased, 283 reduced and 113 closed positions. Its largest new stake was lululemon athletica: 2,588,881 shares worth $315M. The largest sale was Caterpillar, an estimated $680M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jennison Associates's largest Q4 2018 buy was lululemon athletica: 2,588,881 shares worth $315M.
- Jennison Associates added most to Merck in Q4 2018, an estimated $891M increase.
- Jennison Associates's biggest Q4 2018 reduction was Caterpillar, cutting an estimated $680M.
- Jennison Associates fully exited Tiffany & Co. in Q4 2018, selling an estimated $151M.
- Jennison Associates's ten largest holdings make up 30% of its $89.4B portfolio in Q4 2018.
- Jennison Associates opened 95 new positions and closed 113 in Q4 2018.
- Jennison Associates's portfolio value fell 18% quarter-over-quarter to $89.4B.
Based on Jennison Associates's 13F filing for Q4 2018, filed 6 Feb 2019.